Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Poseida Therapeutics Inc's Business Segments
Poseida Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 72
Regions Reported
-
Poseida Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Collaboration Revenue100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue | $ 72 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Poseida Therapeutics Inc
Poseida Therapeutics Inc. is a clinical-stage biotechnology company focused on developing gene therapies for the treatment of various types of cancer and rare genetic diseases. The company was founded in 2015 with a mission to provide life-saving treatments for patients by utilizing its proprietary gene engineering platform technologies.
One of the key areas of expertise for Poseida is the development of CAR-T cell therapies. CAR-T cell therapy involves engineering a patient's T cells to express chimeric antigen receptors (CARs) that can recognize and attack cancer cells. Poseida has developed unique next-generation CAR-Ts, known as P-BCMA-101 and P-PSMA-101, which have shown promising results in early clinical trials for multiple myeloma and prostate cancer.
In addition to CAR-T cell therapy, Poseida is also developing gene therapies using its non-viral piggyBac DNA Modification System. This system enables the precise insertion of therapeutic genes into a patient's genome, allowing for long-term and targeted treatment. The company's pipeline includes gene therapies for multiple myeloma, prostate cancer, solid tumors, and rare genetic diseases like ornithine transcarbamylase (OTC) deficiency.
Poseida's work is supported by a team of highly experienced scientists, researchers, and clinicians who specialize in gene engineering, immunology, and oncology. The company has established collaborations with academic institutions, research organizations, and pharmaceutical companies to accelerate the development and commercialization of its therapies.
Poseida has also developed a robust intellectual property portfolio, including proprietary technologies and methods, to protect its gene engineering platform and therapeutic candidates. This provides a competitive advantage and potentially valuable licensing opportunities in the future.
Being a clinical-stage company, Poseida is actively conducting clinical trials to evaluate the safety and efficacy of its therapies. The company has received orphan drug designations from the U.S. Food and Drug Administration (FDA) for some of its therapeutic candidates, which provides incentives and regulatory support for the development of treatments for rare diseases.
As a biotechnology company, Poseida is committed to addressing unmet medical needs and improving the lives of patients with its innovative gene therapies. With its cutting-edge technology, strong pipeline, and strategic collaborations, Poseida Therapeutics Inc. is well-positioned to make significant contributions to the field of gene therapy and revolutionize the treatment of cancer and rare genetic diseases.
One of the key areas of expertise for Poseida is the development of CAR-T cell therapies. CAR-T cell therapy involves engineering a patient's T cells to express chimeric antigen receptors (CARs) that can recognize and attack cancer cells. Poseida has developed unique next-generation CAR-Ts, known as P-BCMA-101 and P-PSMA-101, which have shown promising results in early clinical trials for multiple myeloma and prostate cancer.
In addition to CAR-T cell therapy, Poseida is also developing gene therapies using its non-viral piggyBac DNA Modification System. This system enables the precise insertion of therapeutic genes into a patient's genome, allowing for long-term and targeted treatment. The company's pipeline includes gene therapies for multiple myeloma, prostate cancer, solid tumors, and rare genetic diseases like ornithine transcarbamylase (OTC) deficiency.
Poseida's work is supported by a team of highly experienced scientists, researchers, and clinicians who specialize in gene engineering, immunology, and oncology. The company has established collaborations with academic institutions, research organizations, and pharmaceutical companies to accelerate the development and commercialization of its therapies.
Poseida has also developed a robust intellectual property portfolio, including proprietary technologies and methods, to protect its gene engineering platform and therapeutic candidates. This provides a competitive advantage and potentially valuable licensing opportunities in the future.
Being a clinical-stage company, Poseida is actively conducting clinical trials to evaluate the safety and efficacy of its therapies. The company has received orphan drug designations from the U.S. Food and Drug Administration (FDA) for some of its therapeutic candidates, which provides incentives and regulatory support for the development of treatments for rare diseases.
As a biotechnology company, Poseida is committed to addressing unmet medical needs and improving the lives of patients with its innovative gene therapies. With its cutting-edge technology, strong pipeline, and strategic collaborations, Poseida Therapeutics Inc. is well-positioned to make significant contributions to the field of gene therapy and revolutionize the treatment of cancer and rare genetic diseases.
Poseida Therapeutics Inc. is a pioneering biotechnology company specializing in the development and commercialization of innovative gene therapies aimed at addressing unmet medical needs across a spectrum of diseases, particularly those that are difficult to treat. The breadth of the companys offerings can be organized into three main categories: segments, products, and services.
1. Segments
Genetic Medicine:
Poseida Therapeutics is dedicated to the advancement of genetic medicine through its proprietary gene engineering technologies. This segment emphasizes pioneering gene therapies that utilize cutting-edge methodologies in gene editing, gene delivery, and gene regulation. The company’s focus rests on developing next-generation therapeutic approaches capable of tackling a wide array of diseases, from rare genetic disorders to complex cancers.
Products
CAR-T Therapies:
Poseida has made significant strides in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. These therapies harness the power of a patient’s own immune system by reengineering T-cells to recognize and attack cancer cells specifically. Poseida’s CAR-T products are designed to improve efficacy and safety profiles, potentially transforming the landscape of cancer treatment.
T-Cell Receptor (TCR) Therapies:
In addition to CAR-T therapies, Poseida Therapeutics is developing TCR therapies that focus on modifying T-cells to identify and destroy cancer cells expressing specific tumor-associated antigens. This approach complements their CAR-T technology, offering a wider range of potential cancer treatments aimed at various tumor types and immune evasion mechanisms.
Gene Therapies:
Poseida Therapeutics specializes in gene therapies that aim to rectify genetic defects or dysfunctions. Utilizing advanced approaches, including CRISPR-Cas9 gene editing technology, the company targets the delivery of therapeutic genes into specific cells. This platform encompasses a variety of genetic disorders, offering hope for conditions that currently lack effective treatment options.
Engineered T-Cell Immunotherapy:
To further bolster immune response against malignancies, Poseida is engaged in the development of engineered T-cell immunotherapy. This innovative product line involves enhancing T-cells with specific receptors or antigens to create a more robust and targeted attack against cancer and other diseases. This approach aims to optimize the body’s natural defenses, leading to improved treatment outcomes.
Services
Research and Development:
The cornerstone of Poseida’s offerings lies in extensive research and development services. The company employs a talented team of scientists and experts specializing in various aspects of gene therapy. Their R&D efforts are focused on discovering novel therapeutic targets, refining existing technologies, and advancing their product pipeline to innovative new treatments.
Preclinical and Clinical Development:
Poseida Therapeutics follows a rigorous process for assessing the safety and efficacy of its gene therapies through preclinical and clinical development. This includes designing and executing animal studies and human clinical trials, collecting vital data that supports therapeutic progression and regulatory submissions.
Regulatory Support:
Navigating the complexities of regulatory approval is a critical aspect of Poseidas operations. The company provides comprehensive regulatory support services, preparing the necessary documentation for submissions, engaging with regulatory bodies, and ensuring compliance with safety standards and regulations throughout the development process.
Manufacturing and Commercialization:
Poseida has established robust manufacturing capabilities to produce gene therapies at scale, facilitating clinical trials and eventual commercialization. The company also strategizes on the commercial aspect of its products, focusing on broad patient access and effective dissemination of their therapies to maximize the positive impact on public health.
Conclusion
In summary, Poseida Therapeutics Inc. offers an extensive suite of segments, products, and services centered around genetic medicine, with particular emphasis on CAR-T and TCR therapies, gene therapies, and engineered T-cell immunotherapies. The company’s commitment to innovation and addressing unmet medical needs underscores its role as a leader in the biotechnology sector, setting the stage for advancements in the treatment of various complex diseases.
1. Segments
Genetic Medicine:
Poseida Therapeutics is dedicated to the advancement of genetic medicine through its proprietary gene engineering technologies. This segment emphasizes pioneering gene therapies that utilize cutting-edge methodologies in gene editing, gene delivery, and gene regulation. The company’s focus rests on developing next-generation therapeutic approaches capable of tackling a wide array of diseases, from rare genetic disorders to complex cancers.
Products
CAR-T Therapies:
Poseida has made significant strides in the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies. These therapies harness the power of a patient’s own immune system by reengineering T-cells to recognize and attack cancer cells specifically. Poseida’s CAR-T products are designed to improve efficacy and safety profiles, potentially transforming the landscape of cancer treatment.
T-Cell Receptor (TCR) Therapies:
In addition to CAR-T therapies, Poseida Therapeutics is developing TCR therapies that focus on modifying T-cells to identify and destroy cancer cells expressing specific tumor-associated antigens. This approach complements their CAR-T technology, offering a wider range of potential cancer treatments aimed at various tumor types and immune evasion mechanisms.
Gene Therapies:
Poseida Therapeutics specializes in gene therapies that aim to rectify genetic defects or dysfunctions. Utilizing advanced approaches, including CRISPR-Cas9 gene editing technology, the company targets the delivery of therapeutic genes into specific cells. This platform encompasses a variety of genetic disorders, offering hope for conditions that currently lack effective treatment options.
Engineered T-Cell Immunotherapy:
To further bolster immune response against malignancies, Poseida is engaged in the development of engineered T-cell immunotherapy. This innovative product line involves enhancing T-cells with specific receptors or antigens to create a more robust and targeted attack against cancer and other diseases. This approach aims to optimize the body’s natural defenses, leading to improved treatment outcomes.
Services
Research and Development:
The cornerstone of Poseida’s offerings lies in extensive research and development services. The company employs a talented team of scientists and experts specializing in various aspects of gene therapy. Their R&D efforts are focused on discovering novel therapeutic targets, refining existing technologies, and advancing their product pipeline to innovative new treatments.
Preclinical and Clinical Development:
Poseida Therapeutics follows a rigorous process for assessing the safety and efficacy of its gene therapies through preclinical and clinical development. This includes designing and executing animal studies and human clinical trials, collecting vital data that supports therapeutic progression and regulatory submissions.
Regulatory Support:
Navigating the complexities of regulatory approval is a critical aspect of Poseidas operations. The company provides comprehensive regulatory support services, preparing the necessary documentation for submissions, engaging with regulatory bodies, and ensuring compliance with safety standards and regulations throughout the development process.
Manufacturing and Commercialization:
Poseida has established robust manufacturing capabilities to produce gene therapies at scale, facilitating clinical trials and eventual commercialization. The company also strategizes on the commercial aspect of its products, focusing on broad patient access and effective dissemination of their therapies to maximize the positive impact on public health.
Conclusion
In summary, Poseida Therapeutics Inc. offers an extensive suite of segments, products, and services centered around genetic medicine, with particular emphasis on CAR-T and TCR therapies, gene therapies, and engineered T-cell immunotherapies. The company’s commitment to innovation and addressing unmet medical needs underscores its role as a leader in the biotechnology sector, setting the stage for advancements in the treatment of various complex diseases.